(±)-6-methoxy-1,1,4a-trimethyl-2,3,4,4a-tetrahydro-1H-fluorene | 1352235-41-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: (±)-6-methoxy-1,1,4a-trimethyl-2,3,4,4a-tetrahydro-1H-fluorene
• 英文别名: 6-methoxy-1,1,4a-trimethyl-2,3,4,4a-tetrahydro-1H-fluoren；6-methoxy-1,1,4a-trimethyl-3,4-dihydro-2H-fluorene
• CAS: 1352235-41-6
• 化学式: C₁₇H₂₂O
• 分子量: 242.361
• InChiKey: YRBZMIQSKLBWDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  在 copper(II) bis(trifluoromethanesulfonate) 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以77%的产率得到(±)-6-methoxy-1,1,4a-trimethyl-2,3,4,4a-tetrahydro-1H-fluorene
  参考文献：
  名称：

  金属三氟甲磺酸酯催化芳基乙烯基甲醇的环化反应：（±）-二氢蒽酮和（±）-台湾四氢醌H † ‡的形式合成

  摘要：

  正式合成二萜类化合物。据报道，具有全碳四元立体中心的台湾醌类（±）-二氢蒽酮（1a）和（±）-台湾醌H（1b）。关键步骤涉及由三氟甲磺酸酯催化的由β-环柠檬醛制得的芳基乙烯基甲醇的环化反应。该反应可能通过芳基烯丙基碳阳离子物质的中间体遵循逐步机理。

  DOI：

  10.1039/c3ra41497c

文献信息

• [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] LIGANDS SE LIANT AUX OPSINES, COMPOSITIONS, ET PROCÉDÉS D'UTILISATION
  申请人：BIKAM PHARMACEUTICALS INC

  公开号：WO2011155983A1

  公开（公告）日：2011-12-15

  Compounds are disclosed that are useful for treating ophthalmic conditions related to mislocalization of opsin proteins, the misfolding of mutant opsin proteins and the production of toxic visual cycle products that accumulate in the eye. Compositions of these compounds, either alone or in combination with other therapeutic agents, are also disclosed, along with thereapeutic methods of using such compositions. Methods of synthesizing such compounds are also described.
• [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] LIGANDS LIANT L'OPSINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：BIKAM PHARMACEUTICALS INC

  公开号：WO2012134971A2

  公开（公告）日：2012-10-04

  Compounds and compositions of said compounds along with methods of use of compounds are disclosed for treating ophthalmic conditions related to mislocalization of opsin proteins, the misfolding of mutant opsin proteins and the production of toxic visual cycle products that accumulate in the eye. Compounds and compositions useful in the these methods, either alone or in combination with other therapeutic agents, are also described, along with methods of use.